APR 246

Drug Profile

APR 246

Alternative Names: APR-246; PRIMA-1-MET; UNII-Z41TGB4080

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aprea
  • Developer Aprea; H. Lee Moffitt Cancer Center and Research Institute
  • Class Antineoplastics; Quinuclidines; Small molecules
  • Mechanism of Action Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Preclinical Lung cancer; Oesophageal cancer
  • No development reported Haematological malignancies; Prostate cancer

Most Recent Events

  • 02 Aug 2017 Aprea Therapeutics initiates enrolment in a phase Ib/II trial for Ovarian cancer (Recurrent, Second-line therapy)
  • 22 Jun 2017 Aprea Therapeutics initiates enrolment in the phase II PiSARRO-R trial for Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater) in Spain (indication) (EudraCT2017-000265-67)
  • 23 May 2017 Phase-I/II clinical trials in Myelodysplastic syndromes (Combination therapy) in USA (IV) (NCT03072043)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top